期刊文献+

人A组轮状病毒结构蛋白VP7原核表达及其卵黄抗体效价的研究 被引量:2

Study on Prokaryotic Expression of Human Group A Rotavirus VP7 Gene and the IgY Anti-VP7 Titer
下载PDF
导出
摘要 为获得人A组轮状病毒重组结构蛋白VP7及其高效价的卵黄抗体,使用PCR技术扩增VP7 DNA片段并将其克隆到原核表达载体pET28a上形成重组质粒pET28a-VP7。将重组质粒转化基因工程菌E.Coil BL21(DE3),用0.5 mM IPTG诱导VP7重组蛋白的表达。通过包涵体纯化和蛋白复性后,将VP7重组蛋白与弗氏佐剂混匀免疫产蛋鸡,收集鸡蛋。用水稀释-盐析法纯化卵黄抗体IgY。进一步应用SDS-PAGE、ELISA和点杂交技术,分析该卵黄抗体的纯度、效价和特异性。结果表明在基因工程菌E.coli BL21(DE3)中能够实现VP7重组抗原的表达,将重组抗原VP7免疫产蛋鸡,提取纯化得到滴度为1:100 000的抗VP7卵黄抗体,且特异性的识别野生型A组轮状病毒。 In order to prepare recombinant constitutive protein VP7 of human A Rotavirus and it's high titer egg yolk antibody(IgY),the VP7 DNA fragment is amplified by PCR and cloned into the prokaryotic expression vectors pET28a to form recombinant plasmid pET28a-VP7. After identification by DNA sequencing,the recombinant plasmids of pET28a-VP7 is transformed into E. coli BL21 and induced with 0. 5 mM IPTG. Next,the recombinant VP7 insoluble protein is purified and refolded,and then subjected to immune lay hens combined with CFA,eggs are collected. Then,anti-VP7 IgY antibodies are purified by water dilution-salt outing. Moreover,the purity,titer and specificity of isolated IgY are further analyzed by SDS-PAGE,ELISA and dot blot respectively. The results show that the recombinant VP7 protein can be expressed in E. coli BL21 as inclusion body. After immunization with VP7 recombinant antigen,the isolated anti-VP7 IgY antibodies demonstrate a high titer at 1∶ 100 000,and recognize wild type human A rotavirus by its' specificity.
出处 《四川理工学院学报(自然科学版)》 CAS 2014年第3期15-19,共5页 Journal of Sichuan University of Science & Engineering(Natural Science Edition)
基金 新疆生物资源基因工程重点实验室开放课题(XJDX0201-2014-01) 四川省战略新兴产业资助项目(10-046-04-Z11) 四川省教育厅项目(12ZA088)
关键词 人A组轮状病毒 VP7 原核表达 包涵体 免疫 卵黄抗体 human A rotavirus VP7 prokaryotic expression inclusion body immune IgY
  • 相关文献

参考文献13

  • 1Vesikari T.Rotavirus vaccimtion:a concise review[J]. Clin Microbiol Infect,2012,18 (5): 1-7. 被引量:1
  • 2Patton J T. Structure and function of the rotavirus RNA- binding proteins [ J ]. J Gen Virol, 1995,76 ( 11 ): 2633- 2644. 被引量:1
  • 3Pesavento J B,Cmwford S E,Estes M K,et al.Rotavirus proteins:structure and assembly[J]. Curr Top Microbiol lmmunol,2006,309:189-219. 被引量:1
  • 4姜琳琳,张孝云,马莉,颜次慧,齐怀丰,熊冬生,范冬梅.基因工程抗体抗CD19(Fab)-LDM的制备及生物学活性研究[J].中国药理学通报,2013,29(10):1363-1368. 被引量:5
  • 5Ludert J E,Ruiz M C,Hidalgo C,et al.Antibodies to rota- virus outer-capsid glycoprotein VP7 neutralize infectivi- ty by inhibiting virion decapsidation[J].J Virol,2002,76: 6643-6651. 被引量:1
  • 6Z0rate S,Romero P,Espinosa R, et aI.VP7 Mediates theInteraction of Rotaviruses with lntegrin etv:3 through a Novel Integrin-Binding Site [J]. J Virol,2004,78:10839- 10847. 被引量:1
  • 7江保明,杨晓明,徐德启.轮状病毒疫苗的现状和发展动向[J].中国生物制品学杂志,2012,25(2):251-253. 被引量:13
  • 8Niraj C,Patel M D,Paula M,et al.Vaccine-acquired rota- virus in infants with severe combined immunodeficiency [J].N Engl J Meal,2010,362:314-319. 被引量:1
  • 9Patel M M, Steele D, Gentsch J R, et al. Real-world impact of mtavirus vaccimtion[J].Pediatr Infect Dis J, 2011,30:1-5. 被引量:1
  • 10Vesikari T.Rotavirus vaccination:a concise review[J].Clin Microbiol Infect,2012,18(5):57-63. 被引量:1

二级参考文献33

  • 1陆德源.医学微生物学(第3版)[M].北京:人民卫生出版社,1989.43. 被引量:7
  • 2Fu C,Tate JE,Jiang B.Effectiveness of Lanzhou lamb rotavirusvaccine against hospitalized gastroenteritis:further analysis andupdate[J].Hum Vaccin,2010,6(11):953. 被引量:1
  • 3Patel MM,L仵pez-Collada VR,Bulhoes MM,et al.Intussuscep-tion risk and health benefits of rotavirus vaccination in Mexicoand Brazil[J].N Engl J Med,2011,364(24):2283-2292. 被引量:1
  • 4Buttery JP,Danchin MH,Lee KJ,et al.Intussusception follow-ing rotavirus vaccine administration:post-marketing surveillancein the national immunization program in Australia[J].Vaccine,2011,29(16):3061-3066. 被引量:1
  • 5McClenahan SD,Krause PR,Uhlenhaut C.Molecular and infec-tivity studies of porcine circovirus in vaccines[J].Vaccine,2011,29(29-30):4745-4753. 被引量:1
  • 6Weycker D,Sofrygin O,Kemner JE,et al.Cost of routine im-munization of young children against rotavirus infection with Ro-tarix versus RotaTeq[J].Vaccine,2009,27(36):4930-4937. 被引量:1
  • 7Jit M,Edmunds WJ.Evaluating rotavirus vaccination in Englandand Wales.Part II.The potential cost-effectiveness of vaccination[J].Vaccine,2007,25(20):3971-3979. 被引量:1
  • 8Newall AT,Beutels P,Macartney K,et al.The cost-effective-ness of rotavirus vaccination in Australia[J].Vaccine,2007,25(52):8851-8860. 被引量:1
  • 9Jiang B,Gentsch JR,Glass RI,et al.Inactivated rotavirus vac-cines:a priority for accelerated vaccine development[J].Vac-cine,2008,26(52):6754-6758. 被引量:1
  • 10Wang Y,Azevedo M,Saif LJ,et al.Inactivated rotavirus vac-cine induces protective immunity in gnotobiotic piglets[J].Vac-cine,2010,28(33):5432-5436. 被引量:1

共引文献25

同被引文献5

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部